Trial reportEuropean journal of nuclear medicine and molecular imaging2003
Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
Trial report in European journal of nuclear medicine and molecular imaging, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- Abdominopelvic imaging in the follow-up of testicular germ-cell tumors in adults: recommendations of the Scrotal and Penile Imaging Working Group of the European Society of Urogenital Radiology.European radiology · 2025Guideline
- Positron emission tomography (PET) in the urooncological evaluation of the small pelvis.World journal of urology · 2007Pooled it
- [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].Der Urologe. Ausg. A · 2004Pooled it
- Nuclear medicine imaging in non-seminomatous germ cell tumors: lessons learned from the past failures.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Intricacies of Radiographic Assessment in Testicular Germ Cell Tumors.Frontiers in oncology · 2020Review
- [Positron emission tomography in germ cell tumors in men : Possibilities and limitations].Der Urologe. Ausg. A · 2019Review
- PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.PET clinics · 2015Review
- 18F-FDG PET/CT impact on testicular tumours clinical management.European journal of nuclear medicine and molecular imaging · 2014Article
- Fusion imaging: a novel staging modality in testis cancer.Journal of Cancer · 2010Article
- Imaging 'the lost tribe': a review of adolescent cancer imaging. Part 1.Cancer imaging : the official publication of the International Cancer Imaging Society · 2009Review
- [Impact of nuclear medicine imaging techniques for lymph node surgery].Der Urologe. Ausg. A · 2009Review
- Surveillance in testicular cancer: who, when, what and how?Cancer imaging : the official publication of the International Cancer Imaging Society · 2007Review
- [Value of imaging for lymph node metastases from renal cell, bladder, prostate, penile, and testicular cancers].Der Urologe. Ausg. A · 2005Review
- Positron emission tomography in uro-oncology.Cancer imaging : the official publication of the International Cancer Imaging Society · 2005Article
- The role of positron emission tomography in germ cell cancer.World journal of urology · 2004Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relapse occurs in 30% of patients with stage I non-seminomatous germ cell tumours (NSGCT) within 1 year after orchiectomy. Whole-body positron emission tomography with fluorine-18 fluorodeoxyglucose (FDG-PET) may detect small metastases when standard staging with computed tomography (CT) and tumour markers is negative. In this study, 46 patients underwent FDG-PET after staging with normal CT and tumour markers. To exclude diagnostic test bias and workup bias, all patients had routine follow-up with repeated CT and tumour marker evaluation, even though the initial FDG-PET was positive. Thirty-six patients have remained disease free with a median follow-up of 48 months (range 24-76). Ten patients (22%) suffered disease relapse after a median of 2 months (range 1-8), and of these, seven had a true positive initial PET with increased uptake of FDG indicating metastatic disease. There were three false negative and no false positive PET scans. The sensitivity, specificity and accuracy of PET were 70%, 100% and 93%, respectively. The sensitivity of detecting small retroperitoneal metastases was 88%. The negative and positive predictive values were 92% and 100%, respectively, whereas the negative predictive value of standard staging procedures was 78%. FDG-PET thus seems to be superior to conventional staging (P=0.06) in stage I NSGCT. This non-invasive method may improve the overall management of patients with NSGCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.